H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Inventiva (IVA) to $24 from $20 and keeps a Buy rating on the shares. If NATIV3 confirms Phase 2b results, lanifibranor could become “the oral backbone of MASH therapy,” says the analyst, who says that Inventiva’s analyst day reinforced lanifibranor’s differentiated positioning as the only oral, once daily pan PPAR agonist in late-stage development for MASH.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- 3 Best Stocks to Buy Now, 10/02/2025, According to Top Analysts
- Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
- Inventiva management to meet with Piper Sandler
- Inventiva Appoints Andrew Obenshain as CEO to Drive U.S. Market Expansion
- Inventiva SA Reports Progress and Challenges in 2025